Elevated FDG uptake in non-tumorous lung regions does not predict immune checkpoint inhibitor–related pneumonitis in lung cancer patients
BackgroundPredictors for checkpoint inhibitor-related pneumonitis (cinrPneumonitis) are desperately needed. This study aimed to investigate the pretreatment standardized uptake value (SUV) on [18F]FDG-PET/CT of non-tumorous lung tissue as a predictive imaging marker for the development of cinrPneumo...
Saved in:
| Main Authors: | Friederike Völter, Lukas Wehlte, Blerina Resuli, Julia Walter, Lea Daisenberger, Maria Ingenerf, Maurice Heimer, Matthias Brendel, Gabriel T. Sheikh, Lena M. Unterrainer, Diego Kauffmann-Guerrero, Thomas Pfluger, Lucie Heinzerling, Amanda Tufman |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-08-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2025.1563030/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Safety and efficacy of the combination of selpercatinib with osimertinib in NSCLC: a case report and review of the literature
by: Blerina Resuli, et al.
Published: (2025-05-01) -
Changes in prescribing patterns and access to immune checkpoint inhibitors in german lung cancer patients – a claims data analysis
by: Julia Walter, et al.
Published: (2025-07-01) -
Treatment Strategies for First-Line PD-L1-Unselected Advanced NSCLC: A Comparative Review of Immunotherapy-Based Regimens by PD-L1 Expression and Clinical Indication
by: Blerina Resuli, et al.
Published: (2025-07-01) -
Simultaneous Occurrence of HER2 Mutations in EGFR Mutant NSCLC: Case Reports
by: Blerina Resuli, MD, et al.
Published: (2024-12-01) -
Safety of brigatinib following alectinib-induced-pneumonitis: Case report
by: Blerina Resuli, et al.
Published: (2025-01-01)